Home » Teva’s Novel Oral Contraceptive Keeps Up With Competitors in Trial
Teva’s Novel Oral Contraceptive Keeps Up With Competitors in Trial
Teva’s ascending-dose, extended-regimen oral contraceptive Quartette is effective at preventing pregnancy and has a comparable safety profile to other oral birth control pills, the company said. Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) was accepted for FDA review Aug. 13 and would be the first ascending-dose, extended-regimen birth control pill.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May